Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adding Street Address To Product Label Likely In AER Guidance – CFSAN

This article was originally published in The Tan Sheet

Executive Summary

FDA appears likely to include a street address recommendation in its guidance for dietary supplement and OTC product adverse event reporting, and a Center for Food Safety and Applied Nutrition executive assures industry the center is considering a guidance, not a rule

You may also be interested in...



Return To Sender, Industry Groups Say Of AER Address Guidance

FDA's recommendation for complete addresses on OTC and dietary supplement product labels in order to comply with the adverse event reporting law exceeds not only Congress's intent, but also the requirements for all other products regulated by the agency, industry groups say

Return To Sender, Industry Groups Say Of AER Address Guidance

FDA's recommendation for complete addresses on OTC and dietary supplement product labels in order to comply with the adverse event reporting law exceeds not only Congress's intent, but also the requirements for all other products regulated by the agency, industry groups say

Return To Sender, Industry Groups Say Of AER Address Guidance

FDA's recommendation for complete addresses on OTC and dietary supplement product labels in order to comply with the adverse event reporting law exceeds not only Congress's intent, but also the requirements for all other products regulated by the agency, industry groups say

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel